The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

Clinical trial NCT07306585 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07306585
Sponsor: HC Biopharma Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

Start date: 2025-12-30
Primary completion: 2027-03-28
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.